Ratings for Neurocrine Biosciences NBIX were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 2 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Neurocrine Biosciences, presenting an average target of $140.88, a high estimate of $153.00, and a low estimate of $127.00. This upward trend is evident, with the current average reflecting a 7.21% increase from the previous average price target of $131.40.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $140.00 | $127.00 |
| Chris Shibutani | Goldman Sachs | Raises | Buy | $153.00 | $134.00 |
| Carter Gould | Barclays | Raises | Overweight | $150.00 | $145.00 |
| Paul Matteis | Stifel | Raises | Buy | $144.00 | $141.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $127.00 | $110.00 |
| David Hoang | Citigroup | Announces | Neutral | $127.00 | - |
| Neena Bitritto-Garg | Deutsche Bank | Announces | Buy | $136.00 | - |
| Sumant Kulkarni | Canaccord Genuity | Maintains | Buy | $150.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Neurocrine Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Neurocrine Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
Get to Know Neurocrine Biosciences Better
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Understanding the Numbers: Neurocrine Biosciences's Finances
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 28.59%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.66%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Neurocrine Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of 3.04%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.14.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
